Meng F - Search Results

1

Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the host.

Tang H, Shao Y, Huang Y, Qiao S, An J, Yan R, Zhao X, Meng F, Du X, Qin FX. Tang H, et al. Among authors: meng f. Signal Transduct Target Ther. 2023 May 23;8(1):211. doi: 10.1038/s41392-023-01449-w. Signal Transduct Target Ther. 2023. PMID: 37221221 Free PMC article. No abstract available.

2

Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.

Li Y, Liu J, Gao L, Liu Y, Meng F, Li X, Qin FX. Li Y, et al. Among authors: meng f. Immunol Lett. 2020 Apr;220:88-96. doi: 10.1016/j.imlet.2019.03.006. Epub 2019 Mar 15. Immunol Lett. 2020. PMID: 30885690 Review.

3

Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.

Du X, Meng F, Peng D, Wang Z, Ouyang W, Han Y, Gu Y, Fan L, Wu F, Jiang X, Xu F, Qin FX. Du X, et al. Among authors: meng f. J Immunol. 2019 Aug 15;203(4):1012-1020. doi: 10.4049/jimmunol.1801557. Epub 2019 Jul 15. J Immunol. 2019. PMID: 31308089

4

Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities.

Du X, Zuo X, Meng F, Wu F, Zhao X, Li C, Cheng G, Qin FX. Du X, et al. Among authors: meng f. Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. doi: 10.1016/j.bbrc.2019.11.065. Epub 2019 Dec 2. Biochem Biophys Res Commun. 2020. PMID: 31806372

5

Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin.

Du X, Zuo X, Meng F, Han C, Ouyang W, Han Y, Gu Y, Zhao X, Xu F, Qin FX. Du X, et al. Among authors: meng f. Cell Prolif. 2021 Jan;54(1):e12953. doi: 10.1111/cpr.12953. Epub 2020 Nov 19. Cell Prolif. 2021. PMID: 33211371 Free PMC article.

6

The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression.

Gao L, Liu Y, Du X, Ma S, Ge M, Tang H, Han C, Zhao X, Liu Y, Shao Y, Wu Z, Zhang L, Meng F, Xiao-Feng Qin F. Gao L, et al. Among authors: meng f. Cell Death Dis. 2021 Jul 5;12(7):680. doi: 10.1038/s41419-021-03968-2. Cell Death Dis. 2021. PMID: 34226519 Free PMC article.

7

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.

Tang H, Gao L, Wu Z, Meng F, Zhao X, Shao Y, Shi X, Qiao S, An J, Du X, Qin FX. Tang H, et al. Among authors: meng f. Front Cell Infect Microbiol. 2021 Oct 13;11:720357. doi: 10.3389/fcimb.2021.720357. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34722330 Free PMC article.

8

Corrigendum: Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.

Tang H, Gao L, Wu Z, Meng F, Zhao X, Shao Y, Shi X, Qiao S, An J, Du X, Qin FX. Tang H, et al. Among authors: meng f. Front Cell Infect Microbiol. 2021 Nov 29;11:813645. doi: 10.3389/fcimb.2021.813645. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34912731 Free PMC article.

9

Omicron adopts a different strategy from Delta and other variants to adapt to host.

Du X, Tang H, Gao L, Wu Z, Meng F, Yan R, Qiao S, An J, Wang C, Qin FX. Du X, et al. Among authors: meng f. Signal Transduct Target Ther. 2022 Feb 10;7(1):45. doi: 10.1038/s41392-022-00903-5. Signal Transduct Target Ther. 2022. PMID: 35145066 Free PMC article. No abstract available.

10

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization.

Tang H, Gao L, Wu Z, Meng F, Zhao X, Shao Y, Hou G, Du X, Qin FX. Tang H, et al. Among authors: meng f. Front Immunol. 2022 Mar 16;13:836232. doi: 10.3389/fimmu.2022.836232. eCollection 2022. Front Immunol. 2022. PMID: 35371108 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,101 results

Search Page

Filters